Area:
synaptic transmission
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Zhen Zhang is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
1999 |
Zhang, Zhen |
R43Activity Code Description: To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s). |
Artificial Neural Network Software For Early Detection O @ Horus Global Healthnet, Inc.
Ovarian cancer is the leading cause of death from gynecologic cancer in the US. For most patients, the disease is first diagnosed at an advanced stage, and the 5-year survival rate is low (<30%). Despite incremental improvement in chemotherapy, the cure rate has not improved significantly in the past decades. The dramatic difference in long-term survival between patients with local disease (80-90%) and those with distant metastases (5- 20%) suggests the need for a non-invasive, yet effective test applicable to at-risk population groups to detect ovarian cancer in early stages. Building upon prior research in differentiating malignant from benign ovarian masses, this project seeks to apply artificial neural network (ANN) technology to the problem of screening for early-stage ovarian cancer based a variety of serum markers and other clinical inputs. Phase I will constitute a pilot project that assesses feasibility by (l) assembling existing data from collaborating organizations, (2) analyzing the predictive value of relevant biomarkers, (3) developing a preliminary ANN, and (4) validating the ANN using independent test data. If successful in Phase I, Phase II activities will be proposed to develop a production version of the screening system and initiate broad-scale validation through multiple clinical studies. PROPOSED COMMERCIAL APPLICATIONS: ANN software capable of detecting early-stage ovarian cancer with sufficient improvement in specificity, sensitivity, and predictive value over alternative techniques would have clear commercial value in screening high-risk populations. Horus presently offers as a commercial product an Internet based clinical information processing service, called ProstAsure, developed using ANN technology, for the detection of prostate cancer.
|
0.921 |